Cg Oncology(NASDAQ) CGON

CG Oncology helps patients with bladder cancer by developing new drug treatments. These medicines aim to kill cancer cells and help the body's immune system fight the disease. The company focuses on people who no longer respond to current standard therapies.

The Product Pipeline

• Cretostimogene: Main drug candidate in late-stage testing for bladder cancer that hasn't reached the muscle wall; acts as an immunotherapy delivered directly into the bladder.
• Combination Therapy: Use of cretostimogene alongside other immune-boosting drugs like pembrolizumab to potentially improve patient outcomes.
• Intermediate-Risk Care: Experimental use of cretostimogene following surgery to prevent cancer from returning in patients with lower-grade tumors.

Strategic Growth and Expansion

• Initiated a Biologics License Application (BLA) for its lead candidate in late 2025 to seek official regulatory approval.
• Acquired Biovire in July 2025 to take direct control over the manufacturing supply of its main drug candidate.
• Maintained a long-term license and collaboration agreement with Kissei Pharmaceutical Co., Ltd. to develop and sell treatments in various Asian markets.
• Partnered with Merck through a clinical trial collaboration to provide drugs for testing combination therapies at no cost.

What Makes the Company Unique

The company focuses on a dual-action approach that kills cancer cells while training the immune system to recognize and attack the disease. Its treatments use a simple delivery method similar to existing standard care, which helps doctors adopt the new technology quickly.

A Look at the Numbers

• Revenue grew to $2.3 million in Q4 2025, a 409% increase from the $456,000 reported in Q4 2024.
• Net losses widened to $41.3 million in Q4 2025 compared to a loss of $31.8 million in Q4 2024.
• Operating cash flow was negative $36.2 million in Q4 2025, down from negative $20.7 million in Q4 2024.
• The company had 113 full-time employees and a market capitalization of $5.9 billion as of early 2026.

The Evolution of CG Oncology

CG Oncology has transitioned from an early research firm to a late-stage clinical company preparing for its first product launch. By securing its own manufacturing and pursuing multiple cancer indications, the company is building a foundation for long-term operations in the biotechnology sector.